<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540758</url>
  </required_header>
  <id_info>
    <org_study_id>2018-9039</org_study_id>
    <secondary_id>R01DK069861</secondary_id>
    <nct_id>NCT03540758</nct_id>
  </id_info>
  <brief_title>Regulation of Endogenous Glucose Production by Central KATP Channels</brief_title>
  <official_title>Regulation of Endogenous Glucose Production by Central KATP Channels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes affects the ability of the body to process glucose (sugar). Under fasting&#xD;
      conditions, the liver is able to make sugar to maintain glucose levels in an important&#xD;
      process called endogenous glucose production (EGP). Previous studies suggest that the central&#xD;
      nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by&#xD;
      communicating with the liver. This process can be impaired in people with type 2 diabetes,&#xD;
      and can contribute to the high level of glucose seen in these individuals.&#xD;
&#xD;
      The purpose of this study is to understand how activating control centers of the brain with a&#xD;
      medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is&#xD;
      particularly important for people with diabetes who have very high production of glucose,&#xD;
      which in turn can lead to diabetes complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will study healthy participants and participants with type 2&#xD;
      diabetes through a procedure called a &quot;pancreatic clamp&quot; study. During the clamp procedure,&#xD;
      glucose (a sugar) and insulin (a hormone produced in the pancreas that regulates the amount&#xD;
      of glucose in the blood) are infused with an intravenous catheter, and blood samples are&#xD;
      collected periodically throughout the procedure to measure blood sugar levels and the levels&#xD;
      of several hormones that are found in the body and are related to glucose metabolism.&#xD;
      Endogenous glucose production (a measure of the body's production of sugar) will be measured&#xD;
      in patients given diazoxide (a medication that activates potassium channels in the brain that&#xD;
      may affect glucose production in the liver through brain-liver signaling), compared with when&#xD;
      a placebo is given. This study will also investigate whether lowering free fatty acid levels&#xD;
      which may help improve the the body's ability to regulate glucose levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In Aim 1, non-diabetic participants will be studied after receiving diazoxide or placebo in a randomized, single-blinded fashion. In Aim 2, participants with type 2 diabetes will be studies after receiving diazoxide or placebo in a randomized, single-blinded fashion. In Aim 3, participants with type 2 diabetes will be studied after receiving diazoxide or placebo in a randomized, single-blinded fashion after lowering their free fatty acid levels.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The subject will be blinded as to which study drug he/she is receiving first (Drug or Placebo).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous glucose production (EGP)</measure>
    <time_frame>7-7.5 hours</time_frame>
    <description>Rates of EGP (a measure of the body's production of sugar) will be measured using analysis of blood samples taken throughout the pancreatic clamp procedure under various treatment conditions (eg, placebo, diazoxide, nicotinic acid, nicotinic acid/diazoxide), by monitoring changes in the level of a non-radioactive, naturally occurring form of glucose (sugar).</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Glucose, High Blood</condition>
  <arm_group>
    <arm_group_label>Non-diabetic (Diazoxide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to non-diabetic participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to non-diabetic participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D (Diazoxide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pancreatic clamp study will be done after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D (Diazoxide + Nicotinic Acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreatic clamp study will be done after giving Diazoxide (Proglycem) oral suspension to type 2 diabetic participants after lowering free fatty acids with a nicotinic acid (Niacin) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D (Nicotinic Acid + placebo for diazoxide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreatic clamp study will be done after lowering free fatty acids with a nicotinic acid (Niacin) infusion in type 2 diabetic participants, and after giving a taste-matched placebo for Diazoxide (Proglycem) to type 2 diabetic participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide</intervention_name>
    <description>Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.&#xD;
T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.</description>
    <arm_group_label>Non-diabetic (Diazoxide)</arm_group_label>
    <arm_group_label>T2D (Diazoxide + Nicotinic Acid)</arm_group_label>
    <arm_group_label>T2D (Diazoxide)</arm_group_label>
    <other_name>Proglycem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinic acid</intervention_name>
    <description>T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.</description>
    <arm_group_label>T2D (Diazoxide + Nicotinic Acid)</arm_group_label>
    <arm_group_label>T2D (Nicotinic Acid + placebo for diazoxide)</arm_group_label>
    <other_name>Niacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.&#xD;
T2D participants will have their blood sugar levels normalized, and will then receive a taste-matched placebo for diazoxide before undergoing the pancreatic clamp study.</description>
    <arm_group_label>Non-diabetic (Placebo)</arm_group_label>
    <arm_group_label>T2D (Nicotinic Acid + placebo for diazoxide)</arm_group_label>
    <arm_group_label>T2D (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For healthy participants:&#xD;
&#xD;
          -  Age: 21-70 y.o.&#xD;
&#xD;
          -  BMI under 35&#xD;
&#xD;
          -  Negative drug screen&#xD;
&#xD;
          -  Normal A1C and fasting glucose&#xD;
&#xD;
          -  No family history of diabetes among first degree relatives (eg. mother, father)&#xD;
&#xD;
        For T2D participants:&#xD;
&#xD;
          -  Age: 21-70 y.o.&#xD;
&#xD;
          -  BMI under 35&#xD;
&#xD;
          -  A1c 8.0-12.0%&#xD;
&#xD;
          -  Negative drug screen&#xD;
&#xD;
          -  Not suffering from a previously diagnosed proliferative retinopathy, significant&#xD;
             diabetic renal disease or severe neuropathy (including cardiovascular and&#xD;
             gastrointestinal autonomic dysfunction).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age: Under 21 or over 70 y.o.&#xD;
&#xD;
          -  BMI: &gt;35&#xD;
&#xD;
          -  Blood pressure &gt;150/90 or &lt;90/60 on more than one occasion&#xD;
&#xD;
          -  Severe polydipsia and polyuria&#xD;
&#xD;
          -  Urine microalbumin: &gt;300 mg/g of creatinine (in subjects with T2D)&#xD;
&#xD;
          -  Uncontrolled hyperlipidemia&#xD;
&#xD;
          -  Clinically significant liver dysfunction&#xD;
&#xD;
          -  Clinically significant kidney dysfunction&#xD;
&#xD;
          -  Clinically significant anemia&#xD;
&#xD;
          -  Clinically significant leukocytosis or leukopenia&#xD;
&#xD;
          -  Clinically significant thrombocytopenia or thrombocytosis&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Positive urine drug screen&#xD;
&#xD;
          -  Urinalysis: Clinically significant abnormalities&#xD;
&#xD;
          -  Clinically significant electrolyte abnormalities&#xD;
&#xD;
          -  Smoking &gt;10 cig/day&#xD;
&#xD;
          -  Alcohol: Men &gt;14 drinks/wk or &gt;4 drinks/day, Women &gt;7 drinks/wk or &gt;3 drinks/day&#xD;
&#xD;
          -  History of chronic liver disease, active hepatitis infection, HIV/AIDS, chronic kidney&#xD;
             disease (stage 3 or greater), active cancer, cardiovascular disease or other heart&#xD;
             disease, systemic rheumatologic conditions, seizures, bleeding disorders, muscle&#xD;
             disease&#xD;
&#xD;
          -  Surgeries that involve removal of endocrine glands except for thyroidectomy&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Subject enrolled in another study less than one month prior to the anticipated start&#xD;
             date of the proposed study, besides those done by our group&#xD;
&#xD;
          -  Family history: family history of premature cardiac death&#xD;
&#xD;
          -  Allergies to medication administered during study&#xD;
&#xD;
          -  Uncontrolled psychiatric disorders&#xD;
&#xD;
          -  Any condition which in the opinion of the PI makes the subject ill suited for&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meredith Hawkins, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meredith Hawkins, M.D., M.S.</last_name>
    <phone>718-430-2903</phone>
    <email>meredith.hawkins@einsteinmed.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meredith Hawkins, M.D., M.S.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Meredith Hawkins</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>diabetes</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>diazoxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Diazoxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

